IDO1 and cancer: The immunoregulatory molecule indoleamine 2,3-dioxygenase 1 (IDO1)—which catalyzes the first, rate-limiting step of Trp degradation through the kynurenine (Kyn) pathway—is highly expressed in many types of human cancers (6, 7) and is generally associated with poor prognosis (8).